1
|
de la Rocha AMA, González-Huarriz M, Guruceaga E, Mihelson N, Tejada-Solís S, Díez-Valle R, Martínez-Vélez N, Fueyo J, Gomez-Manzano C, Alonso MM, Laterra J, López-Bertoni H. Erratum: miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. Arch Clin Biomed Res 2021; 5:425-426. [PMID: 34888488 PMCID: PMC8654198 DOI: 10.26502/acbr.50170176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Arlet María Acanda de la Rocha
- The Health Research Institute of Navarra (IDISNA), USA
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, USA
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
- Department of Environmental Health Sciences. Robert Stempel College of Public Health & Social Work. Florida International University, USA
| | - Marisol González-Huarriz
- The Health Research Institute of Navarra (IDISNA), USA
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, USA
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| | - Elizabeth Guruceaga
- The Health Research Institute of Navarra (IDISNA), USA
- Bioinformatics Unit, Center for Applied Medical Research, Pamplona, Spain
| | - Nicole Mihelson
- Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA
| | - Sonia Tejada-Solís
- The Health Research Institute of Navarra (IDISNA), USA
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, USA
- Department of Neurosurgery, University Hospital of Navarra, Pamplona, Spain
| | - Ricardo Díez-Valle
- The Health Research Institute of Navarra (IDISNA), USA
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, USA
- Department of Neurosurgery, University Hospital of Navarra, Pamplona, Spain
| | - Naiara Martínez-Vélez
- The Health Research Institute of Navarra (IDISNA), USA
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, USA
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| | - Juan Fueyo
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Candelaria Gomez-Manzano
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Marta M Alonso
- The Health Research Institute of Navarra (IDISNA), USA
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, USA
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| | - John Laterra
- Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA
- Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
- Department of Neuroscience, The Johns Hopkins School of Medicine, Baltimore, MD, USA
- Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Hernando López-Bertoni
- Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA
- Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
| |
Collapse
|
2
|
Tejada S, Becerra-Castro MV, Nuñez-Cordoba J, Díez-Valle R. Ki-67 Proliferative Activity in the Tumor Margins as a Robust Prognosis Factor in Glioblastoma Patients. J Neurol Surg A Cent Eur Neurosurg 2020; 82:53-58. [PMID: 33260244 DOI: 10.1055/s-0040-1709730] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
INTRODUCTION The infiltrative margin of glioblastomas (GBM) contains proliferative tumor cells difficult to estimate radiologically as they are included in the hyperintense signal of T2 sequences and they remain in the cavity margin after tumor resection. The amount of these cells could determine overall survival (OS) of these patients. MATERIAL AND METHODS From October 2007 to January 2010, patients whose MRI were suggestive of newly diagnosed, resectable high-grade glioma were operated using fluorescence-guided surgery (FGS). Separate samples were selectively taken from nonfluorescent white matter areas just adjacent to the border of the pale fluorescence and staining was made for Ki-67. OS was analyzed with Kaplan-Meier and Cox regression. Multivariate analysis included the following prognosis variables: age, extent of resection (EOR), O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and performance status index. RESULTS Sample included 65 patients, comprising 37 men and 28 women, with a median Karnofsky Performance Score (KPS) of 80 (40-100) and mean age of 60 (34-78) years. Mean preoperative tumor volume was 35.8 mL. EOR was 100% in 52 patients (80%), with the lower EOR being 88%. For Ki-67, 39 patients had <5% and 26 had ≥5%. OS was 26.8 months (95% confidence interval [CI]: 18.9-28.2) for the Ki-67 low group versus 15.8 months (95% CI: 7.7-18.2) for the Ki-67 high group (p = 0.002). CONCLUSION Proliferative activity in the normal-looking brain around the resection cavity measured with Ki-67 immunostaining is an important independent prognostic factor for GBM cases with complete resection of enhancing tumor. When complete resection is not reached, this factor is not relevant for prognosis.
Collapse
Affiliation(s)
- Sonia Tejada
- Department of Neurosurgery, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | - Jorge Nuñez-Cordoba
- Division of Biostatistics, Universidad de Navarra Facultad de Medicina, Pamplona, Navarra, Spain
| | - Ricardo Díez-Valle
- Department of Neurosurgery, Universidad de Navarra Facultad de Medicina, Pamplona, Navarra, Spain
| |
Collapse
|
3
|
Prieto-Matos C, Garaycochea O, Calavia D, Alegre M, Bejarano B, Huarte A, Díez-Valle R, Zubieta JL, Manrique M. Clinical Profile and Results Obtained in Patients Treated by Auditory Brainstem Implants. Acta Otorrinolaringologica (English Edition) 2020. [DOI: 10.1016/j.otoeng.2019.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
de la Rocha AMA, González-Huarriz M, Guruceaga E, Mihelson N, Tejada-Solís S, Díez-Valle R, Martínez-Vélez N, Fueyo J, Gomez-Manzano C, Alonso MM, Laterra J, López-Bertoni H. miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. ACTA ACUST UNITED AC 2020; 4:221-238. [PMID: 32905473 PMCID: PMC7470213 DOI: 10.26502/acbr.50170100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and prognosis is poor despite maximum therapeutic efforts. GBM is composed of heterogeneous cell populations, among which the glioma stem-like cells (GSCs) play an important role in tumor cell self-renewal and the ability to initiate and drive tumor growth and recurrence. The transcription factor SOX2 is enriched in GSCs where it controls the stem cell phenotype, invasion and maintenance of tumorigenicity. Therefore, understanding the molecular mechanisms governed by SOX2 in GSCs is crucial to developing targeted therapies against this resistant cell population. In this study, we identified and validated a miRNA profile regulated by SOX2 in GSCs. Among these miRNAs, miR-425-5p emerged as a significant robust candidate for further study. The expression of miR-425-5p was significantly enriched in clinical GBM specimens compared with a human brain reference sample and showed a positive correlation with SOX2 expression. Using a combination of in silico analyses and molecular approaches, we show that SOX2 binds to the promoter of miR-425-5p. Loss of function studies show that repressing miR-425-5p expression in multiple GSCs inhibited neurosphere renewal and induced cell death. More importantly, miR-425-5p inhibition extended survival in an orthotopic GBM mouse model. Finally, combining several bioinformatics platforms with biological endpoints in multiple GSC lines, we identified FOXJ3 and RAB31 as high confidence miR-425-5p target genes. Our findings show that miR-425-5p is a GBM stem cell survival factor and that miR-425-5p inhibition function is a potential strategy for treating GBM.
Collapse
Affiliation(s)
- Arlet María Acanda de la Rocha
- The Health Research Institute of Navarra (IDISNA), Spain
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Spain
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
- Department of Environmental Health Sciences. Robert Stempel College of Public Health & Social Work. Florida International University, USA
| | - Marisol González-Huarriz
- The Health Research Institute of Navarra (IDISNA), Spain
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Spain
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| | - Elizabeth Guruceaga
- The Health Research Institute of Navarra (IDISNA), Spain
- Bioinformatics Unit, Center for Applied Medical Research, Pamplona, Spain
| | - Nicole Mihelson
- Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA
| | - Sonia Tejada-Solís
- The Health Research Institute of Navarra (IDISNA), Spain
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Spain
- Department of Neurosurgery, University Hospital of Navarra, Pamplona, Spain
| | - Ricardo Díez-Valle
- The Health Research Institute of Navarra (IDISNA), Spain
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Spain
- Department of Neurosurgery, University Hospital of Navarra, Pamplona, Spain
| | - Naiara Martínez-Vélez
- The Health Research Institute of Navarra (IDISNA), Spain
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Spain
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| | - Juan Fueyo
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Candelaria Gomez-Manzano
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Marta M. Alonso
- The Health Research Institute of Navarra (IDISNA), Spain
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Spain
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| | - John Laterra
- Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA
- Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
- Department of Neuroscience, The Johns Hopkins School of Medicine, Baltimore, MD, USA
- Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Hernando López-Bertoni
- Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA
- Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
- Corresponding author: Hernando López-Bertoni, Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, USA,
| |
Collapse
|
5
|
Puigdelloses M, González-Huárriz M, García-Moure M, Martínez-Vélez N, Esparragosa Vázquez I, Bruna J, Zandio B, Agirre A, Marigil M, Petrirena G, Nuñez-Córdoba JM, Tejada-Solís S, Díez-Valle R, Gállego-Culleré J, Martínez-Vila E, Patiño-García A, Alonso MM, Gállego Pérez-Larraya J. RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases. Neurooncol Adv 2020; 2:vdaa010. [PMID: 32642678 PMCID: PMC7212908 DOI: 10.1093/noajnl/vdaa010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Circulating biomarkers may assist in the processes of differential diagnosis and response assessment. GBM cells release extracellular vesicles containing a subset of proteins and nucleic acids. We previously demonstrated that exosomes isolated from the serum of GBM patients had an increased expression of RNU6-1 compared to healthy subjects. In this exploratory study, we investigated the role of this small noncoding RNA as a diagnostic biomarker for GBM versus other brain lesions with some potential radiological similarities. Methods We analyzed the expression of RNU6-1 in circulating exosomes of GBM patients (n = 18), healthy controls (n = 30), and patients with subacute stroke (n = 30), acute/subacute hemorrhage (n = 30), acute demyelinating lesions (n = 18), brain metastases (n = 21), and primary central nervous system lymphoma (PCNSL; n = 12) using digital droplet PCR. Results Expression of RNU6-1 was significantly higher in GBM patients than in healthy controls (P = .002). RNU6-1 levels were also significantly higher in exosomes from GBM patients than from patients with non-neoplastic lesions (stroke [P = .05], hemorrhage [P = .01], demyelinating lesions [P = .019]) and PCNSL (P = .004). In contrast, no significant differences were found between patients with GBM and brain metastases (P = .573). Receiver operator characteristic curve analyses supported the role of this biomarker in differentiating GBM from subacute stroke, acute/subacute hemorrhage, acute demyelinating lesions, and PCNSL (P < .05), but again not from brain metastases (P = .575). Conclusions Our data suggest that the expression of RNU6-1 in circulating exosomes could be useful for the differentiation of GBM from non-neoplastic brain lesions and PCNSL, but not from brain metastases.
Collapse
Affiliation(s)
- Montserrat Puigdelloses
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain
| | - Marisol González-Huárriz
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain
| | - Marc García-Moure
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain
| | - Naiara Martínez-Vélez
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain
| | - Inés Esparragosa Vázquez
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain
| | - Jordi Bruna
- Department of Neurology, Hospital de Bellvitge, Barcelona, Spain
| | - Beatriz Zandio
- Department of Neurology, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - Amaia Agirre
- POLYMAT, University of the Basque Country, San Sebastian, Spain
| | - Miguel Marigil
- Division of Neurosurgery, Lariboisière University Hospital, Paris, France
| | | | - Jorge M Nuñez-Córdoba
- Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Pamplona, Spain.,Department of Preventive Medicine and Public Health, Medical School, Universidad de Navarra, Pamplona, Spain
| | - Sonia Tejada-Solís
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain
| | - Ricardo Díez-Valle
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain
| | | | - Eduardo Martínez-Vila
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain
| | - Ana Patiño-García
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain
| | - Marta M Alonso
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain
| | - Jaime Gállego Pérez-Larraya
- Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.,Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain
| |
Collapse
|
6
|
Prieto-Matos C, Garaycochea O, Calavia D, Alegre M, Bejarano B, Huarte A, Díez-Valle R, Zubieta JL, Manrique M. Clinical Profile and Results Obtained in Patients Treated by Auditory Brainstem Implants. Acta Otorrinolaringol Esp (Engl Ed) 2020; 71:225-234. [PMID: 31937406 DOI: 10.1016/j.otorri.2019.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2019] [Revised: 08/05/2019] [Accepted: 08/13/2019] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Cochlear implants have been able to treat some types of hearing loss, but those related to cochlear nerve impairment made it necessary to find new ways to manage these deficits; leading to auditory brainstem implants (ABI). AIM Our objective is to present the clinical profile of patients treated through an ABI and the results obtained from 1997 to 2017. MATERIAL AND METHODS On the one hand, patients with statoacoustic nerve tumours (VIIIcranial nerve) were selected, and on the other hand, patients withoutVIII tumours with congenital malformations of the inner ear. Before and after the placement of the ABI, hearing was assessed through tonal audiometry, from which the PTA (Pure Tone Average) and the CAP (Categories of Auditory Performance) scale were obtained. RESULTS A total of 20 patients undergoing ABI surgery were included. Eight were of tumour cause (40%) and 12 non-tumour (60%). In 15 subjects (75%) a suboccipital approach was performed and in 5 (25%) translabyrinthine. The mean of active electrodes before the implantation of Cochlear® (Nucleus ABI24) was 13/21 (61.90%) versus 8.5/12 (70.83%) of the Med-el® (ABI Med-el). An improvement in the mean PTA of 118.49dB was found against 46.55dB at 2years. On the CAP scale, values of1 were obtained in the preimplantation and of 2.57 (1-5) in the 2-year revision. CONCLUSION The ABI is a safe option, and with good hearing results when the indication is made correctly.
Collapse
Affiliation(s)
- Carlos Prieto-Matos
- Departamento de Otorrinolaringología, Clínica Universidad de Navarra, Pamplona, España.
| | - Octavio Garaycochea
- Departamento de Otorrinolaringología, Clínica Universidad de Navarra, Pamplona, España
| | - Diego Calavia
- Departamento de Otorrinolaringología, Clínica Universidad de Navarra, Pamplona, España
| | - Manuel Alegre
- Departamento de Neurofisiología, Clínica Universidad de Navarra, Pamplona, España
| | - Bartolomé Bejarano
- Departamento de Neurocirugía, Clínica Universidad de Navarra, Pamplona, España
| | - Alicia Huarte
- Departamento de Otorrinolaringología, Clínica Universidad de Navarra, Pamplona, España
| | - Ricardo Díez-Valle
- Departamento de Neurocirugía, Clínica Universidad de Navarra, Pamplona, España
| | - José Luis Zubieta
- Departamento de Radiodiagnóstico, Clínica Universidad de Navarra, Pamplona, España
| | - Manuel Manrique
- Departamento de Otorrinolaringología, Clínica Universidad de Navarra, Pamplona, España
| |
Collapse
|
7
|
Iñigo-Marco I, Díez-Valle R, Garcia-Moure M, Patiño-García A, González Huarriz M, Jones C, Gomez-Manzano C, Fueyo J, Alonso MM, Tejada S. PDCT-18 (LTBK-03). PHASE I CLINICAL TRIAL WITH ONCOLYTIC VIRUS DNX-2401 FOR DIPGS. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz219.1197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Delta-24-RGD (DNX-2401 in the clinic) has been tested for adult glioblastoma presenting a safe profile and promising efficacy. Our group has showed that the virus is safe and effective in preclinical models of pHGG and DIPG. Moreover, we showed that the virus is able to trigger an antitumor immune response. These results allowed us to propel a phase I clinical trial for newly diagnosed DIPGs (NCT03178032) where the patients received an intratumoral injection of DNX-2401 (N=12). Tumor biopsy is performed through the cerebellar peduncle, followed by virus injection using a cannula that prevents the reflux. The trial is uncontrolled, unicentric with a 3 + 3 design. The objective of this trial is to determine the safety, tolerability, and toxicity of DNX-2401 in subjects with DIPG. Secondary endpoints are overall survival at 12 months (OS12), percentage of responses and induced immune response against tumor. To date 9 patients have been treated within the trial. Three patients were treated with the D1=1x1010vp and because the lack of toxicity we escalated to the D2= 5x1010vp. The procedure was well tolerated and safe. Patients were home 3–4 days after the injection. All the patients displayed a reduced tumor volume after combined treatment. We performed molecular studies in 8 out of the 9 patients (RNAseq and a thermofisher pediatric panel). Subsequently we evaluated the immune cell composition in the tumor using multiplexed quantitative immunofluorescence on the biopsies pre-virus injection. T cells were hardly noticeable in these tumors while macrophages were abundant. Using a multiplexed TCR-sequencing mRNA-based assay to analyze 18 available paired pre- and post-treatment samples from the trial, we detected increased clonal T cell diversity following treatment with virus. In addition, we are assessing the existence of pre and post treatment neutralizing antibodies and its relationship with survival. Finally, we have performed functional studies using 2 cell lines isolated from patients included in this trials and confronting them with T-cells isolated from peripheral blood of the same patients before and after the treatment with the virus. Information acquired within this clinical study would aid to understand the response of DIPGs to viral therapies and therefore to better tailor this strategy to improve the survival of pediatric brain tumors.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Juan Fueyo
- MD Anderson Cancer Center, Houston, TX, USA
| | | | | |
Collapse
|
8
|
Aldave G, Gonzalez-Huarriz M, Rubio A, Romero JP, Ravi D, Miñana B, Cuadrado-Tejedor M, García-Osta A, Verhaak R, Xipell E, Martinez-Vélez N, de la Rocha AA, Puigdelloses M, García-Moure M, Marigil M, Gállego Pérez-Larraya J, Marín-Bejar O, Huarte M, Carro MS, Ferrarese R, Belda-Iniesta C, Ayuso A, Prat-Acín R, Pastor F, Díez-Valle R, Tejada S, Alonso MM. The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. Neuro Oncol 2019; 20:930-941. [PMID: 29373718 DOI: 10.1093/neuonc/noy007] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Glioblastoma, the most aggressive primary brain tumor, is genetically heterogeneous. Alternative splicing (AS) plays a key role in numerous pathologies, including cancer. The objectives of our study were to determine whether aberrant AS could play a role in the malignant phenotype of glioma and to understand the mechanism underlying its aberrant regulation. Methods We obtained surgical samples from patients with glioblastoma who underwent 5-aminolevulinic fluorescence-guided surgery. Biopsies were taken from the tumor center as well as from adjacent normal-appearing tissue. We used a global splicing array to identify candidate genes aberrantly spliced in these glioblastoma samples. Mechanistic and functional studies were performed to elucidate the role of our top candidate splice variant, BAF45d, in glioblastoma. Results BAF45d is part of the switch/sucrose nonfermentable complex and plays a key role in the development of the CNS. The BAF45d/6A isoform is present in 85% of over 200 glioma samples that have been analyzed and contributes to the malignant glioma phenotype through the maintenance of an undifferentiated cellular state. We demonstrate that BAF45d splicing is mediated by polypyrimidine tract-binding protein 1 (PTBP1) and that BAF45d regulates PTBP1, uncovering a reciprocal interplay between RNA splicing regulation and transcription. Conclusions Our data indicate that AS is a mechanism that contributes to the malignant phenotype of glioblastoma. Understanding the consequences of this biological process will uncover new therapeutic targets for this devastating disease.
Collapse
Affiliation(s)
- Guillermo Aldave
- Division of Pediatric Neurosurgery, Department of Surgery, Texas Children's Hospital, Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
| | - Marisol Gonzalez-Huarriz
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Angel Rubio
- CEIT and TECNUN, University of Navarra, San Sebastian, Spain
| | | | - Datta Ravi
- CEIT and TECNUN, University of Navarra, San Sebastian, Spain
| | - Belén Miñana
- Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain, Universitat Pompeu-Fabra, Barcelona, Spain
| | - Mar Cuadrado-Tejedor
- Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Neurobiology of Alzheimer's Disease, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.,Anatomy Department, School of Medicine, University of Navarra, Pamplona, Spain
| | - Ana García-Osta
- Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Neurobiology of Alzheimer's Disease, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
| | - Roeland Verhaak
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Enric Xipell
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Naiara Martinez-Vélez
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Arlet Acanda de la Rocha
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Montserrat Puigdelloses
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Marc García-Moure
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Miguel Marigil
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Jaime Gállego Pérez-Larraya
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| | - Oskar Marín-Bejar
- Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
| | - Maite Huarte
- Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
| | - Maria Stella Carro
- Department of Neurosurgery (Neurocenter) Universitätsklinikum Freiburg, Freiburg, Germany
| | - Roberto Ferrarese
- Department of Neurosurgery (Neurocenter) Universitätsklinikum Freiburg, Freiburg, Germany
| | | | - Angel Ayuso
- Fundación de Investigación HM Hospitales, Grupo HM, Spain.,Facultad de Medicina, Universidad CEU-San Pablo, Madrid, Spain
| | - Ricardo Prat-Acín
- Department of Neurosurgery, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Fernando Pastor
- Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada, Pamplona, Spain
| | - Ricardo Díez-Valle
- Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain.,Department of Neurosurgery, University Hospital of Navarra, Pamplona, Navarra, Spain
| | - Sonia Tejada
- Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain.,Department of Neurosurgery, University Hospital of Navarra, Pamplona, Navarra, Spain
| | - Marta M Alonso
- Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.,Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.,Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Navarra, Spain
| |
Collapse
|
9
|
Alonso MM, Iñigo I, Gonzalez-Huarriz M, Dominguez P, Patiño A, Jones C, Gomez-Manzano C, Fueyo J, Díez-Valle R, Tejada S. OS5.1 Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Despite our increased understanding of the genetic make-up and new therapies for pediatric high grade glioma (pHGG) and Diffuse Intrinsic Pontine Glioma (DIPG) the outcome remains grim. Delta-24-RGD (DNX-2401 in the clinic) has been tested for adult glioblastoma presenting a safe profile and promising efficacy. Recently our group has showed that the virus is safe and effective in preclinical models of pHGG and DIPG. Moreover, we showed that the virus is able to trigger an antitumor immune response. These outstanding preclinical results allowed us to propel a phase I clinical trial for newly diagnosed DIPGs (NCT03178032) where the patients received an intratumoral viral injection followed by standard radiotherapy.
MATERIALS AND METHODS
A phase I clinical trial with DNX-2401 for patients with newly diagnosed DIPG to assess the MTD is taking place in our hospital (N=12). Tumor biopsy is performed through the cerebellar peduncle, followed by virus injection. The virus is injected using a cannula, MEMS cannula (Alcyone Lifesciences) that prevents the reflux. Virus will be injected starting with 1010 pv. The trial is uncontrolled, unicentric with a 3 + 3 design. The objective of this trial is to determine the safety, tolerability, and toxicity of DNX-2401 in subjects with DIPG and to collect tumor samples of this type of tumor. Secondary endpoints are overall survival at 12 months (OS12), percentage of responses and induced immune response against tumor. The follow up includes close monitoring of neurological status, blood tests and brain MRI. If this trial shows evidence of safety and efficacy will propel a multicenter clinical trial.
RESULTS
All the clinical data from the trial available until September 2019 will be presented during the congress, to date 8 patients have been treated within the trial. Three patients were treated with the D1=1x1010vp and because the lack of toxicity we escalated to the D2= 5x1010vp. The procedure was well tolerated and safe. Patients were home 3–4 days after the injection. All the patients displayed a reduced tumor volume after combined treatment. We performed molecular studies in 6 out of the 8 patients. We are currently assessing the immune responses to the virus.
CONCLUSIONS
Information acquired within this clinical study would aid to understand the response of DIPGs to viral therapies and therefore to better tailor this strategy to improve the survival and the quality of life of pediatric brain tumors.
Collapse
Affiliation(s)
| | - I Iñigo
- University of Navarra, Pamplona, Spain
| | | | | | - A Patiño
- University of Navarra, Pamplona, Spain
| | - C Jones
- Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
| | | | - J Fueyo
- UT MD Anderson Cancer Center, Houston, TX, United States
| | | | - S Tejada
- University of Navarra, Pamplona, Spain
| |
Collapse
|
10
|
Martinez-Velez N, Marigil M, García-Moure M, Gonzalez-Huarriz M, Aristu JJ, Ramos-García LI, Tejada S, Díez-Valle R, Patiño-García A, Becher OJ, Gomez-Manzano C, Fueyo J, Alonso MM. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. Acta Neuropathol Commun 2019; 7:64. [PMID: 31036068 PMCID: PMC6487528 DOI: 10.1186/s40478-019-0714-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2019] [Accepted: 04/02/2019] [Indexed: 01/17/2023] Open
Abstract
Pediatric high grade gliomas (pHGG), including diffuse intrinsic pontine gliomas (DIPGs), are aggressive tumors with a dismal outcome. Radiotherapy (RT) is part of the standard of care of these tumors; however, radiotherapy only leads to a transient clinical improvement. Delta-24-RGD is a genetically engineered tumor-selective adenovirus that has shown safety and clinical efficacy in adults with recurrent gliomas. In this work, we evaluated the feasibility, safety and therapeutic efficacy of Delta-24-RGD in combination with radiotherapy in pHGGs and DIPGs models. Our results showed that the combination of Delta-24-RGD with radiotherapy was feasible and resulted in a synergistic anti-glioma effect in vitro and in vivo in pHGG and DIPG models. Interestingly, Delta-24-RGD treatment led to the downregulation of relevant DNA damage repair proteins, further sensitizing tumors cells to the effect of radiotherapy. Additionally, Delta-24-RGD/radiotherapy treatment significantly increased the trafficking of immune cells (CD3, CD4+ and CD8+) to the tumor niche compared with single treatments. In summary, administration of the Delta-24-RGD/radiotherapy combination to pHGG and DIPG models is safe and significantly increases the overall survival of mice bearing these tumors. Our data offer a rationale for the combination Delta-24-RGD/radiotherapy as a therapeutic option for children with these tumors. SIGNIFICANCE: Delta-24-RGD/radiotherapy administration is safe and significantly increases the survival of treated mice. These positive data underscore the urge to translate this approach to the clinical treatment of children with pHGG and DIPGs.
Collapse
|
11
|
Vallcorba MP, Varela-Guruceaga M, González-Huarriz M, Zandio B, Besora S, Bruna J, Petrirena G, Marigil M, Díez-Valle R, Tejada S, Nuñez J, Alonso MM, Pérez-Larraya JG. CBMT-19. RNU6-1 ANALYSED IN EXOSOMES FROM SERA AS A NOVEL DIFFERENTIAL BIOMARKER FOR GBM VS NON-NEOPLASTIC BRAIN LESIONS AND NSCPL. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | | | - Beatriz Zandio
- Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - Sarah Besora
- Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain
| | - Jordi Bruna
- Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain
| | | | - Miguel Marigil
- Clinica Universidad de Navarra, Pamplona, Navarra, Spain
| | | | - Sonia Tejada
- Clinica Universidad de Navarra, Pamplona, Navarra, Spain
| | - Jorge Nuñez
- Research Support Service, Clínica Universidad de Navarra, Pamplona, Navarra, Spain
| | - Marta M Alonso
- Clinica Universidad de Navarra-CIMA, Pamplona, Navarra, Spain
| | | |
Collapse
|
12
|
Esparragosa I, Díez-Valle R, Tejada S, Gállego Pérez-Larraya J. Management of diffuse glioma. Presse Med 2018; 47:e199-e212. [DOI: 10.1016/j.lpm.2018.04.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 02/13/2018] [Accepted: 04/04/2018] [Indexed: 01/07/2023] Open
|
13
|
Esparragosa I, Inoges S, de Cerio AL, Espinos J, Aristu J, Puigdelloses M, Alonso M, Tejada-Solis S, Díez-Valle R, Gállego Pérez-Larraya J. P01.061 Autologous dendritic cells vaccination and standard radio-chemotherapy in patients with newly diagnosed glioblastoma: a retrospective single-center series. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- I Esparragosa
- Department of Neurology. Clínica Universidad de Navarra, Pamplona, Spain
| | - S Inoges
- Cellular Therapy Laboratory. Clínica Universidad de Navarra, Pamplona, Spain
| | - A L de Cerio
- Department of Neurology. Clínica Universidad de Navarra, Pamplona, Spain
| | - J Espinos
- Department of Radiotherapy & Oncology. Clínica Universidad de Navarra, Pamplona, Spain
| | - J Aristu
- Department of Radiotherapy & Oncology. Clínica Universidad de Navarra, Pamplona, Spain
| | - M Puigdelloses
- Laboratory of Neuro-Oncology. Clínica Universidad de Navarra. CIMA, Pamplona, Spain
| | - M Alonso
- Laboratory of Neuro-Oncology. Clínica Universidad de Navarra. CIMA, Pamplona, Spain
| | - S Tejada-Solis
- Department of Neurosurgery. Clínica Universidad de Navarra, Pamplona, Spain
| | - R Díez-Valle
- Department of Neurosurgery. Clínica Universidad de Navarra, Pamplona, Spain
| | | |
Collapse
|
14
|
Puigdelloses M, González-Huarriz M, Zandio B, Besora S, Bruna J, Petrirena G, Marigil M, Díez-Valle R, Tejada S, Nuñez J, Alonso M, Gállego Pérez-Larraya J. OS1.1 Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - B Zandio
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | - S Besora
- Hospital de Bellvitge, Barcelona, Spain
| | - J Bruna
- Hospital de Bellvitge, Barcelona, Spain
| | | | - M Marigil
- Clinica Universidad de Navarra., Pamplona, Spain
| | - R Díez-Valle
- Clinica Universidad de Navarra., Pamplona, Spain
| | - S Tejada
- Clinica Universidad de Navarra., Pamplona, Spain
| | - J Nuñez
- Research support service. Clínica Universidad de Navarra., Pamplona, Spain
| | - M Alonso
- Clinica Universidad de Navarra. CIMA, Pamplona, Spain
| | | |
Collapse
|
15
|
Tejada S, Díez-Valle R, Domínguez PD, Patiño-García A, González-Huarriz M, Fueyo J, Gomez-Manzano C, Idoate MA, Peterkin J, Alonso MM. DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report. Front Oncol 2018; 8:61. [PMID: 29594041 PMCID: PMC5858123 DOI: 10.3389/fonc.2018.00061] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 02/22/2018] [Indexed: 12/15/2022] Open
Abstract
Diffuse intrinsic pontine gliomas (DIPGs) are aggressive glial brain tumors that primarily affect children, for which there is no curative treatment. Median overall survival is only one year. Currently, the scientific focus is on expanding the knowledge base of the molecular biology of DIPG, and identifying effective therapies. Oncolytic adenovirus DNX-2401 is a replication-competent, genetically modified virus capable of infecting and killing glioma cells, and stimulating an anti-tumor immune response. Clinical trials evaluating intratumoral DNX-2401 in adults with recurrent glioblastoma have demonstrated that the virus has a favorable safety profile and can prolong survival. Subsequently, these results have encouraged the transition of this biologically active therapy from adults into the pediatric population. To this aim, we have designed a clinical Phase I trial for newly diagnosed pediatric DIPG to investigate the feasibility, safety, and preliminary efficacy of delivering DNX-2401 into tumors within the pons following biopsy. This case report presents a pediatric patient enrolled in this ongoing Phase I trial for children and adolescents with newly diagnosed DIPG. The case involves an 8-year-old female patient with radiologically diagnosed DIPG who underwent stereotactic tumor biopsy immediately followed by intratumoral DNX-2401 in the same biopsy track. Because there were no safety concerns or new neurological deficits, the patient was discharged 3 days after the procedures. To our knowledge, this is the first report of intratumoral DNX-2401 for a patient with DIPG in a clinical trial. We plan to demonstrate that intratumoral delivery of an oncolytic virus following tumor biopsy for pediatric patients with DIPG is a novel and feasible approach and that DNX-2401 represents an innovative treatment for the disease.
Collapse
Affiliation(s)
- Sonia Tejada
- Department of Neurosurgery, University Hospital of Navarra, Pamplona, Spain.,The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain
| | - Ricardo Díez-Valle
- Department of Neurosurgery, University Hospital of Navarra, Pamplona, Spain.,The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain
| | - Pablo D Domínguez
- The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.,Department of Radiology, University Hospital of Navarra, Pamplona, Spain
| | - Ana Patiño-García
- The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.,Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| | - Marisol González-Huarriz
- The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain
| | - Juan Fueyo
- Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Cande Gomez-Manzano
- Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | | | | | - Marta M Alonso
- The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.,Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.,Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain
| |
Collapse
|
16
|
Garcia-Moure M, Martínez-Vélez N, Gonzalez-Húarriz M, Puigdelloses M, Patiño-Garcia A, Idoate MA, Díez-Valle R, Tejada S, Gomez-Manzano C, Fueyo J, Alonso MM. MEDU-21. TREATMENT OF PNETS WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD RESULTS IN ANTITUMOR EFFECT. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Marigil M, Martínez-Vélez N, Dominguez P, Idoate MA, Becher OJ, Díez-Valle R, Tejada S, Alonso MM. PCM-14DEVELOPMENT OF A NEW DIPG ORTHOTOPIC MODEL IN MICE USING AN IMPLANTABLE GUIDED-SCREW SYSTEM. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now080.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Aldave G, Huarriz MG, Xipell E, Verhaak R, Tejada-Solís S, Díez-Valle R, Rocha AADL, Martinez-Vélez N, Alonso M. CBIO-03ALTERNATIVE SPLICING IN GLIOBLASTOMA MULTIFORME: CHARACTERIZATION OF Baf45d ABERRANT SPLICING IN THE PATHOGENESIS OF GLIOBLASTOMA. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov209.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Tejada S, Aldave G, Marigil M, Gállego Pérez-Larraya J, Domínguez PD, Díez-Valle R. Erratum to: Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. J Neurooncol 2013. [PMCID: PMC4079614 DOI: 10.1007/s11060-013-1305-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Tejada S, Aldave G, Marigil M, Gállego Pérez-Larraya J, de Gallego J, Domínguez PD, Díez-Valle R. Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. J Neurooncol 2013; 116:169-75. [PMID: 24135848 PMCID: PMC3889292 DOI: 10.1007/s11060-013-1279-z] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2013] [Accepted: 10/09/2013] [Indexed: 11/24/2022]
Abstract
Our purpose was to analyze the pattern of failure in glioblastoma (GBM) patients at first recurrence after radiotherapy and temozolomide and its relationship with different factors. From 77 consecutive GBM patients treated at our institution with fluorescence guided surgery and standard radiochemotherapy, 58 first recurrences were identified and included in a retrospective review. Clinical data including age, Karnofsky performance score, preoperative tumor volume and location, extend of resection, MGMT promoter methylation status, time to progression (PFS), overall survival (OS) and adjuvant therapies were reviewed for every patient. Recurrent tumor location respect the original lesion was the end point of the study. The recurrence pattern was local only in 65.5% of patients and non-local in 34.5%. The univariate and multivariate analysis showed that greater preoperative tumor volume in T1 gadolinium enhanced sequences, was the only variable with statistical signification (p < 0.001) for increased rate of non-local recurrences, although patients with MGMT methylation and complete resection of enhancing tumor presented non-local recurrences more frequently. PFS was longer in patients with non-local recurrences (13.8 vs. 6.4 months; p = 0.019, log-rank). However, OS was not significantly different in both groups (24.0 non-local vs. 19.3 local; p = 0.9). Rate of non-local recurrences in our series of patients treated with fluorescence guided surgery and standard radiochemotherapy was higher than previously published in GBM, especially in patients with longer PFS. Greater preoperative enhancing tumor volume was associated with increased rate of non-local recurrences.
Collapse
Affiliation(s)
- Sonia Tejada
- Department of Neurosurgery, Clínica Universidad de Navarra, C/Pio XII, 36, 31008, Pamplona, Spain,
| | | | | | | | | | | | | |
Collapse
|
21
|
Aldaz B, Sagardoy A, Nogueira L, Guruceaga E, Grande L, Huse JT, Aznar MA, Díez-Valle R, Tejada-Solís S, Alonso MM, Fernandez-Luna JL, Martinez-Climent JA, Malumbres R. Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells. PLoS One 2013; 8:e77098. [PMID: 24155920 PMCID: PMC3796557 DOI: 10.1371/journal.pone.0077098] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 08/29/2013] [Indexed: 11/19/2022] Open
Abstract
Glioblastoma multiforme (GBM)-initiating cells (GICs) represent a tumor subpopulation with neural stem cell-like properties that is responsible for the development, progression and therapeutic resistance of human GBM. We have recently shown that blockade of NFκB pathway promotes terminal differentiation and senescence of GICs both in vitro and in vivo, indicating that induction of differentiation may be a potential therapeutic strategy for GBM. MicroRNAs have been implicated in the pathogenesis of GBM, but a high-throughput analysis of their role in GIC differentiation has not been reported. We have established human GIC cell lines that can be efficiently differentiated into cells expressing astrocytic and neuronal lineage markers. Using this in vitro system, a microarray-based high-throughput analysis to determine global expression changes of microRNAs during differentiation of GICs was performed. A number of changes in the levels of microRNAs were detected in differentiating GICs, including over-expression of hsa-miR-21, hsa-miR-29a, hsa-miR-29b, hsa-miR-221 and hsa-miR-222, and down-regulation of hsa-miR-93 and hsa-miR-106a. Functional studies showed that miR-21 over-expression in GICs induced comparable cell differentiation features and targeted SPRY1 mRNA, which encodes for a negative regulator of neural stem-cell differentiation. In addition, miR-221 and miR-222 inhibition in differentiated cells restored the expression of stem cell markers while reducing differentiation markers. Finally, miR-29a and miR-29b targeted MCL1 mRNA in GICs and increased apoptosis. Our study uncovers the microRNA dynamic expression changes occurring during differentiation of GICs, and identifies miR-21 and miR-221/222 as key regulators of this process.
Collapse
Affiliation(s)
- Beatriz Aldaz
- Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Ainara Sagardoy
- Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
| | - Lorena Nogueira
- Molecular Genetics Unit, Hospital Universitario Marques de Valdecilla and Instituto de Formacion e Investigacion Marques de Valdecilla (IFIMAV), Santander, Spain
| | - Elizabeth Guruceaga
- Unit of Proteomics, Genomics and Bioinformatics, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
| | - Lara Grande
- Molecular Genetics Unit, Hospital Universitario Marques de Valdecilla and Instituto de Formacion e Investigacion Marques de Valdecilla (IFIMAV), Santander, Spain
| | - Jason T. Huse
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Maria A. Aznar
- Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
| | - Ricardo Díez-Valle
- Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - Sonia Tejada-Solís
- Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - Marta M. Alonso
- Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
| | - Jose L. Fernandez-Luna
- Molecular Genetics Unit, Hospital Universitario Marques de Valdecilla and Instituto de Formacion e Investigacion Marques de Valdecilla (IFIMAV), Santander, Spain
| | - Jose A. Martinez-Climent
- Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
- * E-mail: (RM); (JAMC)
| | - Raquel Malumbres
- Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
- * E-mail: (RM); (JAMC)
| |
Collapse
|
22
|
|
23
|
Aldave G, Tejada S, Pay E, Marigil M, Bejarano B, Idoate MA, Díez-Valle R. Prognostic Value of Residual Fluorescent Tissue in Glioblastoma Patients After Gross Total Resection in 5-Aminolevulinic Acid-Guided Surgery. Neurosurgery 2013; 72:915-20; discussion 920-1. [DOI: 10.1227/neu.0b013e31828c3974] [Citation(s) in RCA: 126] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Abstract
BACKGROUND:
There is evidence in the literature supporting that fluorescent tissue signal in fluorescence-guided surgery extends farther than tissue highlighted in gadolinium in T1 sequence magnetic resonance imaging (MRI), which is the standard to quantify the extent of resection.
OBJECTIVE:
To study whether the presence of residual fluorescent tissue after surgery carries a different prognosis for glioblastoma (GBM) cases with complete resection confirmed by MRI.
METHODS:
A retrospective review in our center found 118 consecutive patients with high-grade gliomas operated on with the use of fluorescence-guided surgery with 5-aminolevulinic acid. Within that series, the 52 patients with newly diagnosed GBM and complete resection of enhancing tumor (CRET) in early MRI were selected for analysis. We studied the influence of residual fluorescence in the surgical field on overall survival and neurological complication rate. Multivariate analysis included potential relevant factors: age, Karnofsky Performance Scale, O6-methylguanine methyltransferase methylation promoter status, tumor eloquent location, preoperative tumor volume, and adjuvant therapy.
RESULTS:
The median overall survival was 27.0 months (confidence interval = 22.4-31.6) in patients with nonresidual fluorescence (n = 25) and 17.5 months (confidence interval = 12.5-22.5) for the group with residual fluorescence (n = 27) (P = .015). The influence of residual fluorescence was maintained in the multivariate analysis with all covariables, hazard ratio = 2.5 (P = .041). The neurological complication rate was 18.5% in patients with nonresidual fluorescence and 8% for the group with residual fluorescence (P = .267).
CONCLUSION:
GBM patients with CRET in early MRI and no fluorescent residual tissue had longer overall survival than patients with CRET and residual fluorescent tissue.
Collapse
Affiliation(s)
- Guillermo Aldave
- Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - Sonia Tejada
- Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - Eva Pay
- Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - Miguel Marigil
- Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - Bartolomé Bejarano
- Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - Miguel A. Idoate
- Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain
| | | |
Collapse
|
24
|
Tejada-Solís S, Aldave-Orzaiz G, Pay-Valverde E, Marigil-Sánchez M, Idoate-Gastearena MA, Díez-Valle R. Prognostic value of ventricular wall fluorescence during 5-aminolevulinic-guided surgery for glioblastoma. Acta Neurochir (Wien) 2012; 154:1997-2002; discussion 2002. [PMID: 22930281 DOI: 10.1007/s00701-012-1475-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2012] [Accepted: 08/05/2012] [Indexed: 10/28/2022]
Abstract
BACKGROUND The meaning of the ventricular wall fluorescence during 5-aminolevulinic (5-ALA)-guided surgery in patients with glioblastoma (GBM) is still unknown. The authors studied the association between ventricle fluorescence, clinical outcome and survival, and described the histopathological findings of selective biopsies from the ventricular wall. METHODS One hundred and forty patients diagnosed of GBM underwent fluorescence-guided surgery (FGS); 65 of them were naive GBM and ventricle fluorescence during surgery was annotated prospectively. Selective biopsies were collected from the ventricular wall when possible. Clinical and radiological data were registered, including age, Karnofsky Performance Scale (KPS) score, presence of hydrocephalus, overall survival (OS), tumour volume and location (periventricular vs non-periventricular) and leptomeningeal dissemination. RESULTS During FGS the ventricle wall was opened just when the tumour was periventricular in the preoperative MRI (45 out of 65). In 28 of them (60 %) the fluorescence extended far away from the site of opening, while in 17 it ended just in the few millimetres around the tumour. All four patients who developed hydrocephalus had periventricular tumours and the ventricle wall had been opened during surgery. Statistically significant differences were seen in OS according to periventricular location (15 m vs 33 m, P = 0.008 log rank). However, there was not significant relationship between ventricle fluorescence and hydrocephalus (P = 0.75), nor survival (14 m vs 15.5 m, P = 0.64). CONCLUSIONS Preoperative MRI predicts if the ventricle will be opened using the 5-ALA fluorescence, according to tumour location. It does not predict, however if the ventricle wall is going to be fluorescent or not. The fluorescence of the ventricle wall is not a predictor for complications or survival. Periventricular tumour location is an independent bad prognostic factor in GBM.
Collapse
|
25
|
Prieto E, Martí-Climent JM, Domínguez-Prado I, Garrastachu P, Díez-Valle R, Tejada S, Aristu JJ, Peñuelas I, Arbizu J. Voxel-Based Analysis of Dual-Time-Point 18F-FDG PET Images for Brain Tumor Identification and Delineation. J Nucl Med 2011; 52:865-72. [DOI: 10.2967/jnumed.110.085324] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
26
|
Tejada-Solís S, Díez-Valle R, Domínguez-Echavarri PD, García de Eulate-Ruiz MR, Gómez-Ibáñez A. Infratentorial hygroma secondary to decompressive craniectomy after cerebellar infarction. Neurocirugia (Astur) 2009; 20:470-3. [PMID: 19830371 DOI: 10.1016/s1130-1473(09)70146-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We present a case of expansive CSF collection in the cerebellar convexity. The patient was a 74 years old lady who one month before had suffered a cerebellar infarct complicated with acute hydrocephalus. She had good evolution after decompressive craniectomy without shunting. Fifteen days after surgery, the patient started with new positional vertigo, nausea and vomiting and a wound CSF fistula that needed ventriculoperitoneal shunt (medium pressure) because conservative treatment failed. After shunting, the fistula closed, but the patient symptoms worsened. The MRI showed normal ventricular size with a cerebellar hygroma, extending to the posterior interhemispheric fissure. The collection had no blood signal and expanded during observation. A catheter was implanted in the collection and connected to the shunt. The patient became asymptomatic after surgery, and the hygromas had disappeared in control CT at one month. This case shows an infrequent problem of CSF circulation at posterior fossa that resulted in vertigo of central origin. A higroma-ventricle-peritoneal shunt solved the symptoms of the patient.
Collapse
Affiliation(s)
- S Tejada-Solís
- Departamentos de Neurocirugía . Clínica Universitaria de Navarra
| | | | | | | | | |
Collapse
|
27
|
Tejada-Solís S, Díez-Valle R, Domínguez-Echavarri P, García de Eulate-Ruiz M, Gómez-Ibáñez A. Infratentorial hygroma secondary to decompressive craniectomy after cerebellar infarction. Neurocirugia (Astur) 2009. [DOI: 10.4321/s1130-14732009000500006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
28
|
Irimia P, González-Redondo R, Domínguez PD, Díez-Valle R, Martínez-Vila E. Microvascular decompression may be effective for refractory SUNCT regardless of symptom duration. Cephalalgia 2009; 30:626-30. [DOI: 10.1111/j.1468-2982.2009.01943.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- P Irimia
- Department of Neurology and Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - R González-Redondo
- Department of Neurology and Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - PD Domínguez
- Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain
| | - R Díez-Valle
- Department of Neurology and Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| | - E Martínez-Vila
- Department of Neurology and Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain
| |
Collapse
|